Bayer Q4 Earnings Match Estimates, Xarelto and Eylea Pull Down Sales
BAYRY posts in-line Q4 earnings but revenues miss on lower Xarelto and Eylea sales. 2026 sales guidance signals steady growth ahead.
Zacks·1d ago
More News
Here's Why Bayer Aktiengesellschaft (BAYRY) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·2d ago
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer
LLY, JNJ, SNY and BAYRY ride strong pipelines and M&A momentum as Large-Cap Pharma rebounds in 2026 despite pricing and patent risks.
Zacks·2d ago
4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, BAYRY and Sanofi are worth retaining as the industry shows some recovery.
Zacks·3d ago
CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans
CYTK reports a wider-than-expected Q4 loss as expenses rise, but Myqorzo wins FDA nod and global expansion advances, with $1.22B cash fueling 2026 catalysts.
Zacks·8d ago
Is Align Technology (ALGN) Stock Outpacing Its Medical Peers This Year?
Here is how Align Technology (ALGN) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
Zacks·10d ago
ETFs in Spotlight as Trump Moves to Mobilize Defense Production Act
Trump invokes the Defense Production Act to secure phosphorus and glyphosate. MOO could gain as domestic agricultural and materials players ramp up.
Zacks·14d ago
Bayer (BAYRY) Surges 6.0%: Is This an Indication of Further Gains?
Bayer (BAYRY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·15d ago
NVS Reports Positive Late-Stage Data on Kidney Disease Drug Vanrafia
Novartis posts positive phase III ALIGN data for Vanrafia in IgAN, showing slower kidney decline as it eyes full approval in 2026.
Zacks·20d ago
Will Eylea Sales Decline Weigh on REGN's Top Line in 2026?
Regeneron foresees further Eylea decline in 2026 as biosimilars loom, but Eylea HD, Dupixent and Libtayo aim to steady revenues.